Affordable Access

Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases.

Authors
  • Shuttleworth, Stephen J
  • Bailey, Sarah G
  • Townsend, Paul A
Type
Published Article
Journal
Current drug targets
Publication Date
Nov 01, 2010
Volume
11
Issue
11
Pages
1430–1438
Identifiers
PMID: 20583972
Source
Medline
License
Unknown

Abstract

The development of Histone Deacetylase (HDAC) inhibitors has, until recently, principally been driven by their potential as anti-cancer agents. However, there is emerging evidence that HDAC inhibitors could have utility in the treatment of chronic immune and inflammatory disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, airway hyperresponsiveness and organ transplant rejection. Here we discuss the merits of various, structurally-distinct HDAC inhibitors as potential anti-inflammatory therapeutics and provide examples of the novel medicinal chemistry approaches being undertaken to realize HDAC as a druggable target in this clinical setting.

Report this publication

Statistics

Seen <100 times